Clinical trial
Importance of Type 2 Inflammation in Adults With Cystic Fibrosis and Recurrent Pulmonary Exacerbations
NCT07892443 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Importance of Type 2 Inflammation in Adults With Cystic Fibrosis and Recurrent Pulmonary Exacerbations
- Lead sponsor
- University of Virginia
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- May 31, 2031
- Enrollment
- 100 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cystic fibrosis (cf), type 2 inflammatory disorders
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Baseline Stable-State Absolute Peripheral Blood Eosinophil Count
Absolute peripheral blood eosinophil count measured during clinical stability at baseline. Eosinophil counts will be compared between participants who, after 36 months of prospective observation, are classified as having modulator-refractory CF (average of ≥2 qualifying pulmonary exacerbations per year) or modulator-responsive CF (average of \<2 qualifying pulmonary exacerbations per year).
Papers
PubMed papers this trial cites; 1 paper, results papers first, then newest first.
Lead sponsor's other trials
University of Virginia, most recent start first.
+671 more trials See the organization page
Similar trials
Same condition (Cystic Fibrosis) and phase, most recent start first.
+499 more trials See the condition page